Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients

Journal of Acquired Immune Deficiency Syndromes

Volumn 30, Issue 1, 2002, Pages 105-110

  García de Olalla, Patricia ^a   Knobel, Hernando ^a   Carmona, Alexia ^a   Guelar, Ana ^a   Lôpez Colomés, José L ^a   Caylà, Joan A ^a  

^a Institut Municipal de Salut Publica   (Spain)

Author keywords

Adherence; HAART; HIV infection; Survival

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; COHORT ANALYSIS; DATA ANALYSIS; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; SPAIN; STATISTICAL ANALYSIS; SURVIVAL;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATIENT COMPLIANCE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0036570904     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200205010-00014     Document Type: Article

References (39)

1. Changing patterns of mortality across Europe in patients infected with HIV-1
2. Evolución de la mortalidad y supervivencia del SIDA en Barcelona
3. Assessing the benefits of antiretroviral therapy
4. Viral dynamics of HIV: Implications for drug development and therapeutic strategies
5. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection
6. Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study
7. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response
8. Clinical, biological, and behavioral predictors of early immunologic and virologic response in HIV-infected patients initiating protease inhibitors
9. Non-adherence to triple combination therapy is predictive of AIDS progression and death in HIV-positive men and women
10. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults
11. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome
12. Expanded European AIDS case definition
13. Use of cohort studies for evaluating AIDS therapies
14. Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study
15. Delta: A randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals
16. Factors affecting survival in patients with the acquired immunodeficiency syndrome
17. Regional survival differences across Europe in HIV-positive people: The EuroSIDA study
18. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection
19. Adherence to antiretroviral therapy and Pneumocystis prophylaxis in HIV disease
20. Do HIV-infected injecting drug users over-report adherence to highly active antiretroviral therapy? A comparison between patients' self-reports and serum protease inhibitor concentrations in the French Manif 2000 cohort study
21. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS
22. A randomized, double blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: The INCAS Trial. Italy, The Netherlands, Canada and Australia study
23. CD4-cell count in HIV-1 infected individuals remaining viraemic with highly active antiretroviral therapy (HAART)
24. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients
25. Measuring adherence to antiretroviral medications in clinical trials
26. The measurement of compliance medication taking
27. Adherence assessment to highly active antiretroviral therapy
28. Patient-reported nonadherence to HAART is related to protease inhibitor levels
29. Adherence to triple therapy and viral load response
30. Disease progression, adherence and response to protease inhibitor therapy for HIV infection in an urban Veterans Affairs Medical Center
31. Improving on a coin toss to predict patient adherence to medications
32. Epidemiología del SIDA en Barcelona (1981-1991) (II). Estudio de mortalidad y supervivencia
33. Mortality of HIV-positive and HIV-negative heroin abusers as a function of duration of injecting drug use
34. Impact of HIV infection on non-AIDS mortality among Italian injecting drug users
35. Predictors of mortality in the Amsterdam cohort of human immunodeficiency virus (HIV)-positive and HIV-negative drug users
36. Antiretroviral drug resistance testing in adult HIV-1 infection
37. A comparison study of multiple measures of adherence to HIV protease inhibitors